Literature DB >> 25406200

Tumour-associated osteomalacia and hypoglycaemia in a patient with prostate cancer: is Klotho involved?

Sofiya Bedo Latifyan1, Michel Vanhaeverbeek2, Jean Klastersky1.   

Abstract

Tumour-associated osteomalacia is a paraneoplastic syndrome caused by renal phosphate wasting, leading to severe hypophosphataemia. Excess of circulating fibroblast growth factor 23 (FGF23) is the likely cause, acting via the FGF23/α-Klotho coreceptor, a critical regulator of phosphate metabolism. The other possible effects of that complex in humans are still under investigation. We present a case of an 84-year-old Belgian man, presenting prostate cancer with bone metastases. From June 2010 to March 2013, he presented three episodes of disease progression. From January 2012, the patient developed a progressively marked dorsal kyphosis with significant hypophosphataemia. The calculated TRP (tubular reabsorption of phosphate) was decreased and the FGF23 increased. Mid-March 2013, the patient died after a profound unconsciousness due to hypoglycaemia with hypothermia. We hypothesised that the two paraneoplastic manifestations of this patient (tumour-associated osteomalacia and refractory hypoglycaemia) were due to one cause chain with two main nodes-FGF23 and its coreceptor Klotho.. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25406200      PMCID: PMC4244358          DOI: 10.1136/bcr-2014-206590

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  28 in total

1.  Tumor-induced osteomalacia.

Authors:  Suzanne M Jan de Beur
Journal:  JAMA       Date:  2005-09-14       Impact factor: 56.272

Review 2.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

3.  Mutation of the mouse klotho gene leads to a syndrome resembling ageing.

Authors:  M Kuro-o; Y Matsumura; H Aizawa; H Kawaguchi; T Suga; T Utsugi; Y Ohyama; M Kurabayashi; T Kaname; E Kume; H Iwasaki; A Iida; T Shiraki-Iida; S Nishikawa; R Nagai; Y I Nabeshima
Journal:  Nature       Date:  1997-11-06       Impact factor: 49.962

4.  Severe hypophosphatemic osteomalacia in hormone-refractory prostate cancer metastatic to the skeleton: natural history and pitfalls in management.

Authors:  Rob C M Pelger; Guus A B Lycklama A Nijeholt; Socrates E Papapoulos; Neveen A T Hamdy
Journal:  Bone       Date:  2004-11-24       Impact factor: 4.398

Review 5.  Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism.

Authors:  Jyothsna Gattineni; Michel Baum
Journal:  Pediatr Nephrol       Date:  2009-08-11       Impact factor: 3.714

6.  Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D.

Authors:  Shiguang Liu; Wen Tang; Jianping Zhou; Jason R Stubbs; Qiang Luo; Min Pi; L Darryl Quarles
Journal:  J Am Soc Nephrol       Date:  2006-04-05       Impact factor: 10.121

7.  Decreased insulin production and increased insulin sensitivity in the klotho mutant mouse, a novel animal model for human aging.

Authors:  T Utsugi; T Ohno; Y Ohyama; T Uchiyama; Y Saito; Y Matsumura; H Aizawa; H Itoh; M Kurabayashi; S Kawazu; S Tomono; Y Oka; T Suga; M Kuro-o; Y Nabeshima; R Nagai
Journal:  Metabolism       Date:  2000-09       Impact factor: 8.694

Review 8.  The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis.

Authors:  M Shawkat Razzaque
Journal:  Nat Rev Endocrinol       Date:  2009-11       Impact factor: 43.330

Review 9.  Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization.

Authors:  Shiguang Liu; Aditi Gupta; L Darryl Quarles
Journal:  Curr Opin Nephrol Hypertens       Date:  2007-07       Impact factor: 2.894

10.  Augmented Wnt signaling in a mammalian model of accelerated aging.

Authors:  Hongjun Liu; Maria M Fergusson; Rogerio M Castilho; Jie Liu; Liu Cao; Jichun Chen; Daniela Malide; Ilsa I Rovira; Daniel Schimel; Calvin J Kuo; J Silvio Gutkind; Paul M Hwang; Toren Finkel
Journal:  Science       Date:  2007-08-10       Impact factor: 47.728

View more
  4 in total

1.  Calcitriol Elevation Is Associated with a Higher Risk of Refractory Hypercalcemia of Malignancy in Solid Tumors.

Authors:  Tariq Chukir; Yi Liu; Katherine Hoffman; John P Bilezikian; Azeez Farooki
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

2.  Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23.

Authors:  Nobuaki Ito; Takuo Kubota; Sachiko Kitanaka; Ikuma Fujiwara; Masanori Adachi; Yasuhiro Takeuchi; Hitomi Yamagami; Takehide Kimura; Tatsuya Shinoda; Masanori Minagawa; Ryo Okazaki; Keiichi Ozono; Yoshiki Seino; Seiji Fukumoto
Journal:  J Bone Miner Metab       Date:  2021-07-13       Impact factor: 2.626

3.  Tumor-induced Osteomalacia Caused by a Parotid Tumor.

Authors:  Yuichi Takashi; Yuka Kinoshita; Nobuaki Ito; Manabu Taguchi; Masaaki Takahashi; Naoya Egami; Shogo Tajima; Masaomi Nangaku; Seiji Fukumoto
Journal:  Intern Med       Date:  2017-03-01       Impact factor: 1.271

Review 4.  Tumor-Induced Osteomalacia: A Systematic Clinical Review of 895 Cases.

Authors:  Ariadne Bosman; Andrea Palermo; Julien Vanderhulst; Suzanne M Jan De Beur; Seiji Fukumoto; Salvatore Minisola; Weibo Xia; Jean-Jacques Body; M Carola Zillikens
Journal:  Calcif Tissue Int       Date:  2022-07-20       Impact factor: 4.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.